Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 1996

View Archived Issues

NIH seeks licensees for dual topoisomerase/tubulin polymerization inhibitor

Enzon selects Medac as marketing partner for Oncaspar

SRI and Taiho to develop new approach to breast cancer

Human chorionic gonadotropin use in Kaposi's sarcoma described: NIH seeks licensees

INSERM claims antitumor antibody

MAb 1DT3-D disclosed for treatment of B-cell lymphoma

Novel APC-based method for producing cancer therapeutics and vaccines available for licensing

NIH offers peptides with OMT residues as potential therapeutic agents

DAG analogues as potent PKC agonists available for licensing

Hybridon anti-VEGF antisense compounds for neovascularization disorders

New antitumor agent from Banyu

CRC Technology reports antitumor activity of DF-203

Follow-up confirms safety of PN-27.1

GV-1301 and GV-1302 available for licensing

NIH seeks licensees for novel laminin molecule that lacks affinity for collagen IV

NIH seeks to license invention related to compounds inducing apoptosis

Japanese researchers disclose anticancer applications of the E1AF gene

Selective killing of p53-deficient human tumor cells with mutant adenovirus

Aviron-NeuroVir gene therapy alliance

Genzyme and NCI sign CRADA for melanoma gene therapy

Polypeptide product of DRA gene as potential therapy in colorectal carcinoma available for licensing

Ciba Vision licenses novel antiglaucoma agent from Ueno

Lilly claims compounds for menopausal disorders

Antiobesity proteins described by Lilly

Bristol-Myers Squibb describes potent and selective beta3-adrenoceptor agonist

Nicotine inhaler for smoking cessation: Clinical trial results

New therapeutic for smoking cessation to enter pivotal trials

Genzyme launches HDL cholesterol test in the U.S.

Diagnostic Products expands its array of allergy tests

Nymox prepares filings for Alzheimer's diagnostic test

Techtide P829 in phase III for detecting the spread of melanoma

European approval recommended for LeukoScan

FDA accepts EchoGen filing

IRS-2 polypeptide for diagnosis of insulin- or immune-related disorders available for licensing

Licensees sought for antibodies specific for P31 antigen for use in lung cancer detection

Cell motility factor with potential in cancer diagnostics and therapeutics available for licensing

Pharmacopeia receives patent coverage for drug discovery technology

P&U reports compounds for improving drug bioavailability

Megabios in vivo gene delivery systems available for licensing

ImmunoGen's antibody humanization technology reported to be superior to conventional methods

Medarex receives federal funding for Bispecific technology

KS Biomedix-Roche antibody collaboration

Five SBIR grants awarded to GeneMedicine

NIH seeks licensees for method of detecting cardiac electrical activity

Name change for Biological Detection

Roberts will acquire manufacturing plant from Searle

Vyrex forms new nutraceutical division

Huhtamaki sells pharmaceutical division

Cephalon to sell manufacturing facility

Proposed biotech merger

Acquisition of NemaPharm by Sequana completed

Hemagen to acquire Cellular Products

Cypress and PRP sign merger agreement

Fujisawa sets up North American R&D center

Kirin Brewery reveals Southeast Asia development plans

Company Profile: Prolifix

Company Profile: Institute for Drug Research

Company Profile: Variagenics

Talipexole now available in Japan

Cephalosporin tested in Italian patients with ALS

Spotlight on ALS research

Twenty-four drugs in development for Alzheimer's disease in U.S.

Two Alzheimer's drugs in phase III in Japan

Glaxo Wellcome claims NMDA antagonists

SCRAS claims NOS inhibitors

Daiichi reports calmodulin inhibitors

Clinical trials with Bradycor suspended pending clarification of anomalous animal findings

NS-1201 available for licensing

Efficacy of Ampligen demonstrated in chronic fatigue syndrome

Steroid does not adequately improve symptoms of chronic fatigue syndrome

Japanese launch for ebastine announced

Rhone-Poulenc Rorer seeks to extend use of antiallergic agent to young children

Novel bronchodilators described by Pierre Fabre

Lilly discloses 5-LO inhibitors

Potent, non-redox 5-LO inhibitor identified by Merck Frosst

Chiroscience selects clinical candidate for asthma

Rhone-Poulenc Rorer submits sNDA for new Tilade formulation

Ohmeda and AGA expand agreement on NO

Gelsolin enters clinical trials

GV-1101 available for licensing

Phase IV study results reported for ramipril

Gensia turns over development of Geomatrix nifedipine product

GV-1201/GV-1202 available for licensing

PLC Systems' Heart Laser superior to holmium and excimer lasers for TMR

Antiarrhythmic compounds described by SKB

AM-140 available for licensing

cGMP PDE inhibitors reported by DuPont Merck

Progress on Neuprex for hemorrhagic trauma

Anti-TNF MAb effective in treating septic shock in two major studies

Promising preliminary phase II results for argatroban in acute MI

Transgenic ATIII proven safe in healthy volunteers

Muscarinic antagonists from Yamanouchi

Anti-H. pylori agents discovered by Terumo

CCK-B/gastrin antagonists from Chugai

Safety and efficacy of oral H. pylori vaccine demonstrated in patients

New prokinetic agents from Janssen

Thymosin alpha 1 effective and safe for the treatment of hepatitis B

AM-4055 available for licensing

Fourth viral protease structure solved by Agouron

Theratechnologies-Beaufour Ipsen agreement on TH-9506

Neurex broadens clinical program for SNX-111

Anesta's Actiq on schedule for launch

Antimigraine agents with affinity for 5-HT receptors reported by Pierre Fabre

Novel antimigraine agent launched in the U.K.

Glaxo Wellcome anesthetic receives European clearance

VEGF-B, potential angiogenesis stimulant

Successful completion of Dermagraft pivotal trial

Absorbent wound dressing cleared for launch in the U.S.

Glaxo Wellcome to develop Glylorin

Cholestyramine treatment of peri-anal irritation in an infant

New cephalosporin derivatives from Roche

Natural antibacterial chitinase inhibitors

Key patents issued covering Applied Microbiology's lanthocins

Seventeenth approval for Amphocil/Amphotec

Expanded indications for Abelcet

Torii prepares agents for HIV infection

Water-soluble prodrug of HIV protease inhibitor reported by DuPont Merck

Nucleotide analogue enters clinical trials for HIV

Expanded access program allowed for Remune

AM-1401 available for licensing

Synthetic HIV-1 and HIV-2 proteases from NIH available for licensing

NIH offers synthetic HIV protease gene for design of HIV-1 protease inhibitors

Transframe peptide inhibitors of viral protease for use in therapeutics, diagnostics and vaccines

Licensees sought for retroviral protease inhibitors with novel non-peptidic and achiral substituents

Novel retroviral agents for HIV infection available for licensing

MMP/TNF production inhibitors reported by Pfizer

NIH seeks licensees for antigenic MMP peptides with potential as therapeutic and diagnostic agents

Sulfasalazine approved for rheumatoid arthritis

PRIMATIZED monoclonal antibody proven safe and effective for rheumatoid arthritis

AM-425 available for licensing

Key lupus patent issued to Genelabs

Abbott to market North American Vaccine's DTaP and related vaccines

Procept seeks partners for immunosuppression, AIDS, CD2 programs

AM-101 available for licensing

AM-94 available for licensing

NCI to codevelop MGI anticancer drug

Additional clinical data support the potential of DepoCyt in neoplastic meningitis

Therapeutic polyamine compounds available from NIH

IND for GL-331 approved in Taiwan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...